Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683383 | 0.82 | MAPT (0.52) | NPC1KCNQ3KCNQ2MEN1KMT2A | |
| SCHEMBL24670696 | 0.81 | RAB9A (0.65) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL29803640 | 0.81 | RAB9A (0.65) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL29803287 | 0.81 | MAOB (0.59) | RAB9ANPC1KCNQ3KCNQ2MEN1 | |
| SCHEMBL24670851 | 0.81 | MAOB (0.59) | RAB9ANPC1KCNQ3KCNQ2MEN1 | |
| SCHEMBL4727649 | 0.80 | KCNQ3 (0.58) | RAB9ANPC1KCNQ3KCNQ2MEN1 | |
| SCHEMBL2682582 | 0.79 | ABL1 (0.53) | RAB9ANPC1KCNQ3KCNQ2MEN1 | |
| SCHEMBL24670735 | 0.78 | MAOB (0.62) | RAB9ANPC1KCNQ3KCNQ2MEN1 | |
| SCHEMBL30182470 | 0.77 | RAB9A (0.60) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL4257363 | 0.77 | NPC1 (0.65) | RAB9ANPC1KCNQ3KCNQ2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2635571-B1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8921372-B2 | Inhibitors of hepatitis C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2635571-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | Theravance, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| CN-103189371-A | Novel hepatitis c virus inhibitors | THERAVANCE INC | 2013-07-03 | — | — | CN | disclosed |
| WO-2012061552-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | HAVCR2, SLC10A1, HDGF | RAB9A 2645/4885NPC1 73/4885KCNQ3 4064/4885 |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | RAB9A 1595/4885NPC1 47/4885KCNQ3 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.